The Inherited Neuropathy Consortium (INC) RDCRC is a network of clinical investigators dedicated to developing the infrastructure necessary to evaluate therapies for patients with heritable peripheral neuropathies, collectively known as Charcot-Marie-Tooth disease (CMT). Originally, the INC consisted of six sites. Supplemental funding from the Muscular Dystrophy Association (MDA) and Charcot Marie Tooth Association (CMTA) has allowed us to expand to 17 sites. CMT is caused by mutations in >70 genes. Mutations cause dominantly inherited demyelinating CMT (CMT1), dominantly inherited axonal CMT (CMT2), and recessively inherited CMT (CMT4). Despite scientific advances there are currently no medications to slow progression for any form. In part this is due to the lack of adequate natural history data, the lack of sensitive outcome measures and the lack of biomarkers for CMT. In addition, there has not been a coordinated international effort to share clinical data on patients. We have addressed these areas during our initial cycle of the INC. We have performed natural history studies, generated and tested outcome instruments for adults and children with CMT, and begun testing potential biomarkers. We have developed patient reported outcome (PRO) instruments. We have worked as an international group such that we will enroll >5000 patients into our protocols by the end of our initial five year cycle. We have developed a Web Page that provides information to patients, families and investigators. It also has allowed us to directly interact with patients through our INC Contact Registry and have developed the CMT-lnternational Database (CMT-ID), that consists of national registries from around the world that use the same CMT Minimal Dataset that is used by the INC. Finally, we have trained a number of young investigators who are committed to a career investigating CMT. In our second cycle we propose Aims to extend our natural history data, to extend our Next Generation Sequencing data, to identify potential biomarkers and outcome measures, to perform clinical trials, and to provide information to patients, families and investigators through our INC Website.

Public Health Relevance

The overview provides a description of the groups of inherited neuropathies covered in the INC RDCRC and the INC scientific and administrative leadership and multidisciplinary team that comprise the consortium. We discuss the goals and objectives of the projects, describe the role of the INC Patient Advocacy Groups and both INC Website and research environment. Our plans to generate a central IRB and our progress during the previous cycle are also presented.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Gwinn, Katrina
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Schools of Medicine
Iowa City
United States
Zip Code
Rebelo, Adriana P; Abrams, Alexander J; Cottenie, Ellen et al. (2016) Cryptic Amyloidogenic Elements in the 3' UTRs of Neurofilament Genes Trigger Axonal Neuropathy. Am J Hum Genet 98:597-614
Rossor, Alexander M; Tomaselli, Pedro J; Reilly, Mary M (2016) Recent advances in the genetic neuropathies. Curr Opin Neurol 29:537-48
Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66
Auer-Grumbach, Michaela; Toegel, Stefan; Schabhüttl, Maria et al. (2016) Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies. Am J Hum Genet 99:607-23
Hu, Bo; Arpag, Sezgi; Zuchner, Stephan et al. (2016) A novel missense mutation of CMT2P alters transcription machinery. Ann Neurol 80:834-845
Lunn, Michael P; Ellis, Lauren; Hadden, Robert D et al. (2016) A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst 21:33-7
Mademan, Inès; Harmuth, Florian; Giordano, Ilaria et al. (2016) Multisystemic SYNE1 ataxia: confirming the high frequency and extending the mutational and phenotypic spectrum. Brain 139:e46
Begg, Lindy; McLaughlin, Patrick; Vicaretti, Mauro et al. (2016) Total contact cast wall load in patients with a plantar forefoot ulcer and diabetes. J Foot Ankle Res 9:2
Manole, Andreea; Chelban, Viorica; Haridy, Nourelhoda A et al. (2016) Severe axonal neuropathy is a late manifestation of SPG11. J Neurol 263:2278-2286
Motley, William W; Palaima, Paulius; Yum, Sabrina W et al. (2016) De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease. Brain 139:1649-56

Showing the most recent 10 out of 136 publications